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Abstract
Background: Primary hepatocellular carcinoma (HCC) is one of the most common malignancies in the world.
However, the molecular pathogenesis of HCC is not well-understood, and the prognosis for patients with HCC
remains very poor.
Methods: To disclose detailed genetic mechanisms in hepatocellular carcinoma (HCC) with a view toward
development of novel therapeutic targets, we analyzed expression profiles HCCs and their corresponding
noncancerous tissues by using bioinformatics method.
Results: In this paper, we report the identification of genes whose expression has been altered and the changed
bio-pathways during hepatocarcinogenesis. Hepatoma cells infect intracellular and intercellular signal transduction
through Focal adhesion and cause abnormal expression of important intracellular signaling pathway. In addition, it
is worth mentioning that some small molecules still restored to the state similar to normal cells, such as bambuterol
and lovastatin. This member gene set would serve as a pool of lead gene targets for the identification and
development of novel diagnostic and therapeutic biomarkers to greatly improve the clinical management of
HCC patients with different risks of recurrence after curative partial hepatectomy.
Conclusions: The study has great significance for gene therapy and pharmacotherapy and provides a new
treatment entry point and a potential new clinical drug for HCC patients.
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Background
Primary hepatocellular carcinoma (HCC) is one of the
most common malignancies in the world [1]. The causes
of HCC are better understood than those of other can-
cers in humans. The major risk factors for HCC are
chronic hepatitis and exposure to various exogenous car-
cinogens, including aflatoxin B1 [2]. However, the mo-
lecular pathogenesis of HCC is not well-understood, and
the prognosis for patients with HCC remains very poor.
Like other cancers, HCC demonstrates diverse biological
phenotypes, such as proliferation rate, ability to invade
vessels and so forth. So, gene expression profiling ana-
lysis of HCC provides a clue to clarifying the detailed
mechanisms of hepatocarcinogenesis and discovering
target molecules for the development of novel thera-
peutic drugs.
Classic in vivo carcinogenesis experiments reveal a
higher susceptibility to HCC in male rodents [3-5].
These findings suggest that biologic features of the
tumor may differ significantly between the sexes, but
the reasons remain unclear. In a recent study, investiga-
tors hypothesized that estrogen inhibits the induction of
interleukin 6 produced by Kupffer cells [6]. That the
serum level of interleukin 6 is elevated in several can-
cers has been confirmed [7,8].
In this paper, we report the identification of genes
whose expression has been altered and the changes in
biopathways during hepatocarcinogenesis. The changes
in mitogen-activated protein kinase (MAPK) signaling
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pathways, T-cell receptor signaling pathway, transforming
growth factor β (TGF-β) signaling pathway and neurotro-
phin signaling pathway changed the apoptosis pathway
and hematopoietic cell lineage pathways, so that the liver
cells showed a unique pathology. In addition, it is worth
mentioning that some small molecules were restored to a
state similar to normal cells after treatment with agents
such as bambuterol and lovastatin. This has great signifi-
cance for gene therapy and pharmacotherapy and provides
a new treatment entry point and a potential new clinical
drug for HCC patients.
Methods
Gene expression profiles of hepatoma cells and normal cells
In order to explore the differentially expressed genes and
possible pathogenesis mechanisms in hepatoma cells com-
pared to normal cells, we collected hepatoma cells and
normal cells from different individuals, then we performed
DNA microarrays and obtained the genetic profiles. The
appropriate expression profiling was researched and ob-
tained from the public functional genomics data repositor-
ies Gene Expression Omnibus (GEO) (http://www.ncbi.
nlm.nih.gov/geo/) and the European Molecular Biology La-
boratory–European Bioinformatics Institute (EMBL-EBI)
ArrayExpress. All gene microarrays of hepatoma cells con-
sisted of 32 gene microarrays of hepatoma cells from the
GPL96 platform in ArrayExpress and 10 gene microarrays
of normal cells from ArrayExpress. GEO data are based on
the Affymetrix GPL571 platform data (Affymetrix Human
Genome U133A 2.0 Array). We downloaded the original
Affymetrix CEL files and the platform probe annotation in-
formation file for the next step in bioinformatics analysis.
Extraction of differentially expressed genes
Microarray data were analyzed using the R software
(v.2.13.0) platform [9]. First, we normalized the different
chips by robust multichip averaging [10] and then com-
pared them with the difference using the linear regres-
sion model package limma [11] to get the differentially
expressed genes between the different treatments.
Gene Ontology analysis of differentially -expressed genes
In order to find the changes and function enrichment of
differentially expressed genes at the cellular level, we
used the Gene Ontology (GO) database [12] to classify
the gene function and location information. We per-
formed GO clustering analysis using the clusterProfiler
software package [13,14], then deduced the affinity of
these differentially expressed genes to the cells by clus-
tering the cells within their molecular functions and bio-
logical processes.
Biopathways data analysis
In order to understand the metabolic changes that occur
in hepatoma cells at the cellular level, we obtained the
metabolic and nonmetabolic pathways from the Kyoto
Encyclopedia of Genes and Genomes (KEGG) PATHWAY
database, which is authoritative, and made use of the
Database for Annotation, Visualization and Integrated Dis-
covery website (DAVID; http://david.abcc.ncifcrf.gov/) to
analyze the differentially expressed genes using the method
of KEGG PATHWAY cluster [9,14] for the changed path-
ways involved in the hepatoma cells.
Little molecular expression profiling data analysis
The Connectivity Map (cmap) database contains the ex-
pression data of the genomewide transcription of human
cells in the activity of small-molecule intervention, includ-
ing the 6100 group of small-molecule interference experi-
ments (small interfering group and normal control group)
and the expression profile of 7056 [15]. We analyzed gene
expression differences between normal cells and hepatoma
cells and compared the differentially expressed genes
caused by these small interfering expression genes with
the hope of identifying similar gene expression profiles of
normal cells and hepatoma cells or, vice versa, a small
interfering group. The differentially expressed genes of
normal cells and hepatoma cells were divided into two cat-
egories: upregulation and downregulation. We obtained
an enrichment value which stands for similarity through
Gene Set Enrichment Analysis compared with the differ-
entially expressed genes in the cmap database dealing with
small molecules, whose value was between −1 and 1. The
closer they were to 1, the more the small molecules were
able to simulate the state of normal cells. The closer they
were to −1, the more the small molecules were able to
simulate the state of the hepatoma cells.
Results
Identifying the genes expressed differently in various
pathological states
We used the classic t-test to examine the expression
profiles of hepatoma cells and normal cells and obtained
the differentially expressed genes of hepatoma cells. We
calculated P-values for all genes by performing a t-test.
The P-values were calculated and then adjusted using
the Benjamini–Hochberg (BH) method. Selecting a BH
P value <0.05 as the significance threshold, the expres-
sion of 9,775 gene probes were changed, relating to
4,470 genes.
Gene Ontology clustering of differentially expressed
genes
Cellular components, molecular functions and biological
processes were individually assessed by analyzing GO
clustering on differentially expressed genes, and in each
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kind of function we obtained the most significant 10
terms, as shown in Tables 1, 2 and 3, respectively.
On the basis of the clustering results, when hepatoma
cells occurred, the most significant changes were in cell
membranes and cell nuclei. In addition, there were kin-
ase and protein binding changes which were classic mo-
lecular functions of cell signaling transformation. All the
changes caused by molecules were closely related to can-
cer, and the progress, proliferation and apoptosis of cells
were all significantly clustered.
Biopathways in hepatoma cells
When normal cells become cancerous, their expression
profiles have a significant change, as do some genes. In
this study, we selected differentially expressed genes to
perform GO analysis of the KEGG PATHWAY with the
aim of finding the changed pathways in hepatoma cells.
Setting the false discovery rate at <0.05 and at least two
genes in the signaling pathway as the limiting condi-
tions, we obtained significantly changed pathways, which
are shown in Table 4.
Compared with normal cells, the changes in hepatoma
cells focus on signal transduction. These changes pro-
mote hepatoma cells resistant to the body’s own immune
system and that interfere with the role of some drugs.
The focal adhesion pathway of hepatoma cells changes
a lot. The focal adhesion pathway, which connects cells
with the extracellular matrix, plays a key role in the mo-
tility, proliferation and differentiation of cells. Some of
these connections serve as the connection structure be-
tween signaling receptors on the cell membrane and
intracellular actin protein filaments, and even as direct
signaling molecules, including various protein kinases
and phosphatases. Therefore, changes in this pathway
can block the normal signaling pathways in cells, so that
the hepatoma cells changes sequentially.
Because of the blocking of signal transduction, a series
of important cell signaling pathways change. The MAPK
signaling pathway is an important intracellular signaling
pathway regulating gene expression and plays an important
role in the regulation of cell proliferation, differentiation
and movement. The T-cell receptor signaling pathway is an
important immune signaling pathway whose signals dir-
ectly regulate T-cell proliferation. Therefore, the changes in
this pathway may be the key for hepatoma cells to avoid
autoimmunity. The changes in the TGF-β signaling path-
way and the neurotrophin signaling pathway promote the
formation of an independent group of hepatoma cells that
can be distinguished from normal cells. It is worth men-
tioning that the hematopoietic cell lineage pathway also
changes, which may make it easy to transfer the character-
istics of the source. The final outcome of these changed
signaling pathways changed the apoptosis pathway and the
hematopoietic cell lineage pathway, so that the liver cells
showed a unique pathology.
Exploring the small effector molecules
cmap can be used to find the potential therapeutic drug
candidates which are similar to the drug in hypoxic
Table 1 Gene Ontology clustering of cellular components
Cellular component False discovery rate
[GO:0000267] Cell fraction 4.69E-26
[GO:0044459] Plasma membrane part 1.09E-25
[GO:0005654] Nucleoplasm 1.73E-25
[GO:0005829] Cytosol 1.83E-23
[GO:0005887] Integral to plasma membrane 3.54E-21
[GO:0031226] Intrinsic to plasma membrane 6.36E-21
[GO:0043233] Organelle lumen 4.62E-20
[GO:0031974] Membrane-enclosed lumen 2.00E-18
[GO:0031981] Nuclear lumen 8.71E-18
[GO:0070013] Intracellular organelle lumen 1.06E-16
Table 2 Gene Ontology clustering of molecular functions
Molecular function False discovery
rate
[GO:0004672] Protein kinase activity 1.62E-14
[GO:0004713] Protein tyrosine kinase activity 3.31E-09
[GO:0008134] Transcription factor binding 4.72E-08
[GO:0046983] Protein dimerization activity 5.15E-08
[GO:0019899] Enzyme binding 6.45E-08
[GO:0019838] Growth factor binding 6.44E-07
[GO:0004714] Transmembrane receptor protein
tyrosine kinase activity
7.72E-07
[GO:0042802] Identical protein binding 2.16E-06
[GO:0030528] Transcription regulator activity 2.95E-06
[GO:0019900] Kinase binding 4.94E-06
Table 3 Gene Ontology clustering of biological processes
Biological process False discovery
rate
[GO:0042127] Regulation of cell proliferation 5.99E-28
[GO:0010033] Response to organic substance 1.59E-24
[GO:0006796] Phosphate metabolic process 9.04E-22
[GO:0006793] Phosphorus metabolic process 9.04E-22
[GO:0043067] Regulation of programmed cell death 7.77E-21
[GO:0010941] Regulation of cell death 8.31E-21
[GO:0042981] Regulation of apoptosis 1.75E-20
[GO:0006468] Protein amino acid phosphorylation 3.14E-19
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stimulus conditions and gene expression [15]. It is the
first installment of a reference collection of gene expres-
sion profiles from cultured human cells treated with bio-
active small molecules, together with pattern-matching
software to mine these data [15,16]. To compare normal
cells with hepatoma cells, the differentially expressed
genes were divided into upregulation and downregula-
tion. Compared with the differentially expressed genes
in the cmap database by Gene Set Enrichment Analysis,
we obtained some small molecules similar to normal
cells or hepatoma cells. Twenty small molecules which
had the strongest correlation with hepatoma cells (P-value
minimum) were selected, and these are shown in Table 5
(all processing of small molecules and the effect of repres-
sion of low similarity are shown.
The results showed that the first small molecules could
not simulate the state of normal cells well (enrichment
<0.9). It is worth mentioning, however, that some small
molecules returned to a state similar to that of normal cells
with the use of drugs such as bambuterol (enrichment =
0.667) and lovastatin (enrichment = 0.658). In addition, we
found some molecules with strong carcinogenic effects,
such as pyrvinium (enrichment = −0.818) and ticarcillin
(enrichment = −0.846).
Discussions
HCC is a common and aggressive cancer that occurs
mainly in men. The incidence is associated with gender,
age and duration of the underlying liver disease. How-
ever, the most powerful risk factor is the existence of
liver cirrhosis, regardless of its etiology [17]. High-
volume alcohol intake is associated with the highest risk
[18,19]. Aflatoxin intake also has a role in the genesis of
HCC, but only in patients who have preexisting chronic
hepatitis B [20]. Although great advancements have been
made in the surgical treatment of HCC, tumor recur-
rence after surgery remains a key challenge for the clin-
ical management of HCC patients [21].
In our study, we selected different individual tissues to
analyze biochips with the aim of finding core HCC lesions
(all data from Wang et al. [22]). Specifically, there were
621, 231, 29 and 37 reported probe sets representing 406,
153, 12 and 20 genes, respectively, from the studies of Lee
et al. [23], Ye et al. [24], Iizuka et al. [25] and Kurokawa
et al. [26], respectively. We excluded individual differences
in order to find the common features, in which we found
that as many as 9,775 genes that transcend individual dif-
ferences affect the activity of the cells, showing that hepa-
toma cells indeed have some common features. Expression
of the detoxification enzyme cytochrome P450 and en-
zymes involved in metabolism (AS3MT and HEXB) that
are predominantly expressed in differentiated hepatocytes
were downregulated in recurrent HCC samples. All tissue
samples used in this study were approved and provided by
the Tissue Repository of the National Cancer Centre,
Singapore, and the study was conducted in accordance
with the institution’s ethics committee policies.
The biopathways obtained after GO clustering of differ-
entially expressed genes indicate that the commonality of
hepatoma cells is tracked. Hepatoma cells infect intracel-
lular and intercellular signal transduction through focal
adhesion and cause abnormal expression of important
intracellular signaling pathways (T-cell receptor signaling
pathway, MAPK signaling pathway, TGF-β signaling path-
way and neurotrophin signaling pathway). On the one
Table 4 KEGG biopathway changes in hepatoma cellsa
Term False discovery rate
[hsa04010] MAPK signaling pathway 2.70E-09
[hsa05200] Pathways in cancer 9.90E-06
[hsa04510] Focal adhesion 0.001997
[hsa04660] T-cell receptor signaling pathway 0.002519
[hsa04640] Hematopoietic cell lineage 0.003705
[hsa05220] Chronic myeloid leukemia 0.020022
[hsa05212] Pancreatic cancer 0.034797
[hsa04350] TGF-β signaling pathway 0.041718
[hsa04722] Neurotrophin signaling pathway 0.046962
aKEGG, Kyoto Encyclopedia of Genes and Genomes; MAPK, mitogen-activated
protein kinase; TGF-β, transforming growth factor β.
Table 5 Small effector moleculesa
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hand, hepatoma cells block the body’s own immune re-
sponse and affect cell apoptosis and proliferation. On the
other hand, they change the morphological and behavioral
characteristics of normal cells, transforming them into
cancer cells and eventually leading to the occurrence of
liver cancer. Hence, a better understanding of the clinico-
pathologic features and molecular aspects of HCC, as well
as the ability to assess and stratify patients with different
risk levels of disease recurrence at the time of diagnosis,
would be extremely beneficial for the clinical management
of HCC. This member gene set could serve as a pool of
leading gene targets for the identification and develop-
ment of novel diagnostic and therapeutic biomarkers to
greatly improve the clinical management of HCC patients
with different risks of recurrence after curative partial
hepatectomy.
About 50 randomized controlled trials (RCTs) have been
conducted to develop treatments for HCC patients, but
transarterial embolization and tamoxifen administration
are the only two options that have been best evaluated.
The administration of tamoxifen, an estrogen receptor
blocker, was initially reported to improve survival in pa-
tients with advanced HCC [27]. The activity of chemother-
apy in patients with HCC is negligible. New agents with
relevant activity are needed and will have to be tested
within RCTs. On the basis of differentially expressed genes
and information from the cmap database of small mole-
cules, we found a series of small molecules. These small
molecules can simulate to some extent the different states
of hepatoma cells compared to normal cells, meaning that
these small molecules may be able to repair disorders of
liver metabolic pathways.
Conclusions
The study has great significance for gene therapy and
pharmacotherapy and provides a new treatment entry
point and a potential new clinical drug for HCC patients.
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